What is Modern Age?
Modern Age operates as a pioneering healthcare entity dedicated to the science of slowing down the biological impacts of aging. By integrating cutting-edge research with proactive, evidence-backed treatments, the company addresses under-diagnosed health concerns that typically manifest during the aging process. Its market position is unique, bridging the gap between traditional clinical care and consumer-facing wellness, offering patients a structured, personalized roadmap to maintain physical and mental peak performance. With physical locations in New York City, the company combines a digital-first approach with high-touch, in-person medical services to ensure comprehensive patient engagement.
How much funding has Modern Age raised?
Modern Age has raised a total of $33M across 2 funding rounds:
Angel/Seed
$6M
Series A
$27M
Angel/Seed (2021): $6M with participation from Juxtapose
Series A (2021): $27M led by Oak HC/FT, Juxtapose, and GV
Key Investors in Modern Age
Oak HC/FT
A premier venture growth-equity fund specializing in Healthcare Information and Services, providing strategic counsel and board-level expertise to transformative companies.
GV
A global venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences and frontier technology innovations.
Juxtapose
A venture studio that partners with founders to build and scale market-defining companies from the ground up.
What's next for Modern Age?
With the successful closure of this major enterprise-level funding, Modern Age is expected to scale its clinical infrastructure and enhance its proprietary diagnostic capabilities. The strategic focus will likely shift toward broadening its service portfolio and potentially expanding its physical presence beyond the New York metropolitan area. As the company matures, the integration of advanced health analytics will be critical in maintaining its competitive edge in the longevity market, ensuring that its personalized treatment models remain at the forefront of medical innovation. Investors will be monitoring the firm's ability to translate this capital into measurable improvements in patient healthspan and long-term clinical outcomes.
See full Modern Age company page
